Related Experiment Videos
Procainamide-induced myositis
Abstract:
The risk of developing a syndrome resembling lupus erythematosus when taking procainamide has been well recognized for over 15 years, although the development of myopathy has been reported on one occasion only, in this instance without histopathological evidence of muscle inflammation. The patient reported in this paper developed a severe, rapidly progressive vasculitis, apparently limited to muscle, after taking procainamide for 42 months, his myopathy remitting rapidly after withdrawal of the drug and a short course of treatment with azathioprine. Although this man had no clinical evidence of SLE, he had impressive immunological evidence to support this diagnosis.
Insights
Procainamide can cause lupus-like symptoms and myopathy. This case highlights a severe vasculitis linked to procainamide, which improved after drug withdrawal and treatment, suggesting a drug-induced autoimmune response.
Area of Science:
- Rheumatology
- Clinical Pharmacology
- Neurology
Background:
- Procainamide is known to induce a lupus-like syndrome.
- Drug-induced myopathy is a rare complication of procainamide therapy.
- Previous reports of myopathy lacked histopathological evidence of inflammation.
Purpose of the Study:
- To report a case of severe, rapidly progressive myopathy associated with procainamide use.
- To investigate the potential link between procainamide and drug-induced vasculitis affecting muscle.
- To describe the treatment and outcome of this rare adverse drug reaction.
Main Methods:
- Case report of a patient with myopathy after long-term procainamide use.
- Clinical assessment for systemic lupus erythematosus (SLE) and muscle inflammation.
- Immunological testing to support autoimmune diagnosis.
- Monitoring of symptoms after drug withdrawal and treatment.
Main Results:
- The patient developed severe myopathy and vasculitis after 42 months of procainamide.
- Muscle symptoms rapidly improved upon discontinuation of procainamide.
- Azathioprine treatment facilitated the remission of myopathy.
- Significant immunological evidence supported a diagnosis resembling SLE, despite no clinical SLE features.
Conclusions:
- Procainamide can induce severe myopathy and vasculitis, mimicking autoimmune conditions.
- Early recognition and drug withdrawal are crucial for managing procainamide-induced myopathy.
- Immunosuppressive therapy may be beneficial in resolving these drug-induced autoimmune phenomena.